Literature DB >> 20712800

Health care transition in thalassemia: pediatric to adult-oriented care.

Laurice Levine1, Matthew Levine.   

Abstract

Improved technology and medical advances have increased the lifespan for people with thalassemia. As thalassemia is no longer exclusively a pediatric blood disorder, consideration must now be given to transition planning from pediatric to adult care. The complexity of thalassemia disease, coupled with the changing face of U.S. health care, creates barriers to transitional planning. Additional barriers develop because this chronic disease is less common in adults, leaving caregivers unprepared to facilitate proper adult treatment. This paper will discuss two common U.S. health care settings where care is provided to adults with thalassemia. It will also offer health care administrators, providers, policy makers, and the thalassemia community at large some recommendations on the provision of comprehensive, quality care to assure the best possible outcomes no matter what setting is available to adult patients living with thalassemia.

Entities:  

Mesh:

Year:  2010        PMID: 20712800     DOI: 10.1111/j.1749-6632.2010.05598.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

Review 1.  Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatment.

Authors:  Gibran Ali; Muhammad Akram Tariq; Kamran Shahid; Fridoon Jawad Ahmad; Javed Akram
Journal:  Gene Ther       Date:  2020-04-30       Impact factor: 5.250

2.  Health Related Quality of Life, Depression, Anxiety and Stress in Patients with Beta-Thalassemia Major.

Authors:  M Adib-Hajbaghery; M Ahmadi; Poormansouri S
Journal:  Iran J Ped Hematol Oncol       Date:  2015-12-10

3.  Gene Therapy For Beta-Thalassemia: Updated Perspectives.

Authors:  Garyfalia Karponi; Nikolaos Zogas
Journal:  Appl Clin Genet       Date:  2019-09-23

4.  Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.).

Authors:  Hossein Safizadeh; Zahra Farahmandinia; Simin Soltani Nejad; Nasim Pourdamghan; Majid Araste
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-03       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.